Latest Conference Articles

January 17th 2021, 11:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

January 17th 2021, 8:55pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

January 17th 2021, 7:37pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Infigratinib was found to be associated with encouraging clinical activity with a manageable safety profile in patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.

January 17th 2021, 7:23pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.

January 17th 2021, 4:07pm

Gastrointestinal Cancers Symposium (ASCO GI)

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

January 17th 2021, 4:04pm

Gastrointestinal Cancers Symposium (ASCO GI)

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

January 17th 2021, 1:35am

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

January 16th 2021, 8:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

January 16th 2021, 7:11pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.

January 16th 2021, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

January 16th 2021, 6:56pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

January 16th 2021, 6:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.

January 16th 2021, 4:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

January 16th 2021, 3:15pm

ASCO GI 2021 News

3

January 16th 2021, 3:15pm

ASCO GI 2021 News

2

January 16th 2021, 3:15pm

ASCO GI 2021 News

1

January 16th 2021, 3:30am

Gastrointestinal Cancers Symposium (ASCO GI)

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

January 15th 2021, 10:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

January 15th 2021, 9:45pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.

January 15th 2021, 9:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.